

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

MYLAN PHARMACEUTICALS INC.,  
MSN LABORATORIES PRIVATE LTD.,  
and MSN PHARMACEUTICALS INC.,  
Petitioners,

v.

BAUSCH HEALTH IRELAND LIMITED,  
Patent Owner.

---

IPR2022-00722<sup>1</sup>  
Patent 7,041,786 B2

---

**PETITIONER MYLAN'S NOTICE OF APPEAL**

---

<sup>1</sup> IPR2023-00016 has been joined with this proceeding.

Petitioner Mylan Pharmaceuticals Inc. (“Mylan”) appeals to the United States Court of Appeals for the Federal Circuit from the Patent Trial and Appeal Board’s Final Written Decision in this inter partes review entered on September 8, 2023, (Paper 78), and from all other underlying orders, decisions, rulings, and opinions. 35 U.S.C. §§141(c) and 319. This notice of appeal is timely. 35 U.S.C. §142; 37 C.F.R. §90.2(a).

For the limited purpose of addressing the Director of the United States Patent and Trademark Office’s additional requirements in 37 C.F.R. §90.2(a)(3)(ii), the issues on appeal include the Board’s determination that claims 1-6 of U.S. Patent No. 7,041,786 B2 are not unpatentable. The issues on appeal also include any finding or determination supporting or related to these issues, as well as all other issues decided adversely to Mylan in any order, decision, ruling, or opinion.

Mylan is simultaneously filing this notice with the Director and serving it on patentee Bausch Health Ireland Limited and the MSN petitioners. 37 C.F.R. §§42.6(e), 90.2(a)(1). Mylan is also filing this notice, along with the required fees, with the Clerk’s Office for the United States Court of Appeals for the Federal Circuit. Fed. Cir. R. 15(a)(1).

Respectfully submitted,

Dated: September 28, 2023

/Jad A. Mills/  
Jad A. Mills, Reg. No. 63,344  
*Counsel for Mylan Pharmaceuticals Inc.*

**CERTIFICATES OF FILING AND SERVICE**

I hereby certify that, in addition to filing through the Patent Trial and Appeal Board's P-TACTS system, Mylan filed this notice today by Express Mail with the Director of the United States Patent and Trademark Office, at the following address:

Director of the U.S. Patent and Trademark Office  
c/o Office of the General Counsel  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

.....

I hereby certify that Mylan filed a true and correct copy of this notice today by CM/ECF, with the Clerk's Office of the United States Court of Appeals for the Federal Circuit.

.....

I certify that Mylan served a true and correct copy of this notice today at the patentee's electronic service addresses as follows:

Justin J. Hasford	<a href="mailto:justin.hasford@finnegan.com">justin.hasford@finnegan.com</a>
Bryan C. Diner	<a href="mailto:bryan.diner@finnegan.com">bryan.diner@finnegan.com</a>
Joshua L. Goldberg	<a href="mailto:joshua.goldberg@finnegan.com">joshua.goldberg@finnegan.com</a>
Caitlin E. O'Connell	<a href="mailto:caitlin.oconnell@finnegan.com">caitlin.oconnell@finnegan.com</a>
Kyu Yun Kim	<a href="mailto:kyuyun.kim@finnegan.com">kyuyun.kim@finnegan.com</a>
Kassandra Officer	<a href="mailto:kassandra.officer@finnegan.com">kassandra.officer@finnegan.com</a>
Lauren J. Robinson	<a href="mailto:lauren.robinson@finnegan.com">lauren.robinson@finnegan.com</a>

and on joinder counsel as follows:

Andrew Larsen

[alarsen@merchanted.com](mailto:alarsen@merchanted.com)

Melissa Hayworth

[mhayworth@merchanted.com](mailto:mhayworth@merchanted.com)

Christopher J. Sorenson

[csorenson@merchanted.com](mailto:csorenson@merchanted.com)

Richard J. Berman

[richard.berman@afslaw.com](mailto:richard.berman@afslaw.com)

Bradford C. Frese

[bradford.frese@afslaw.com](mailto:bradford.frese@afslaw.com)

Respectfully submitted,

Dated: September 28, 2023

/Jad A. Mills /

Jad A. Mills, Reg. No. 63,344

*Counsel for Mylan Pharmaceuticals Inc.*